<b>Conclusions:</b> Comprehensive genomic profiling in NSCLC revealed a high prevalence of clinically relevant mutations, with <i>TP53</i>, <i>KRAS</i> and <i>EGFR</i> as the dominant drivers. This evidence concerns the gene KRAS and non-small cell lung carcinoma.